ACTRN12610000067077已完成1 期
Safety and efficacy of cell immunotherapy to treat hepatitis C virus (HCV) infection
Eric J Gowans0 个研究点目标入组 15 人开始时间: 2010年1月20日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 70 Years（—）
- 性别
- All
入选标准
- •HCV ribonuclei acid (RNA) positive for >6 months.
- •Previously failed interferon-based therapy
- •Infected with genotype 1 virus.
排除标准
- •Hepatitis B virus (HBV)-positive
- •Human immunodeficiency virus (HIV)-positive
- •Evidence of autoimmunity
研究者
相似试验
尚未招募
不适用
Investigate the safety and efficacy of small cell lung cancer,Kidney cancer and Primary liver cancer immunotherapyHistopathologically confirmed small cell lung cancer (SCLC)Histopathologically confirmed Kidney cancerHistopathologically confirmed Liver cancerACTRN12618001337268The First Teaching Hospital, Inner Mongolia Medical University50
进行中（未招募）
1 期
The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients, affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.Severe Haemophilia AMedDRA version: 20.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850EUCTR2012-002554-23-ITOCTAPHARMA AG108
进行中（未招募）
1 期
The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients ,affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.Severe Haemophilia AMedDRA version: 20.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850EUCTR2012-002554-23-PLOCTAPHARMA AG108
进行中（未招募）
1 期
The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients ,affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.Severe Haemophilia AMedDRA version: 18.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850EUCTR2012-002554-23-HROCTAPHARMA AG108
进行中（未招募）
1 期
The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients ,affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.Severe Haemophilia AMedDRA version: 20.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850EUCTR2012-002554-23-PTOCTAPHARMA AG100